Nimotuzumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Nimotuzumab
Accession Number
DB06192
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description
Not Available
Protein structure
Db06192
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • Nimotuzumab
International/Other Brands
DiaCIM / RadioTheraCIM / TheraCIM / Theraloc
Categories
UNII
6NS400BXKH
CAS number
780758-10-3

Pharmacology

Indication

Investigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Nimotuzumab.
AbituzumabThe risk or severity of adverse effects can be increased when Nimotuzumab is combined with Abituzumab.
AbrilumabThe risk or severity of adverse effects can be increased when Nimotuzumab is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Nimotuzumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Nimotuzumab.
AducanumabThe risk or severity of adverse effects can be increased when Nimotuzumab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Nimotuzumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nimotuzumab.
AlirocumabThe risk or severity of adverse effects can be increased when Nimotuzumab is combined with Alirocumab.
AmatuximabThe risk or severity of adverse effects can be increased when Nimotuzumab is combined with Amatuximab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Nimotuzumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAdvanced Esophageal1
1CompletedTreatmentAdvanced and/or Metastatic Solid Tumours1
1Not Yet RecruitingTreatmentAdaptive Transfer / ADCC / Cancer, Advanced / Nimotuzumab / NK Cell Mediated Immunity1
1Unknown StatusTreatmentTumors, Solid1
1WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2CompletedTreatmentUterine Cervical Cancer1
1, 2RecruitingTreatmentEGFR Gene Mutations / Recurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1, 2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2Unknown StatusTreatmentEsophageal Squamous Cell Cancer1
1, 2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2Active Not RecruitingTreatmentCervical Cancers1
2Active Not RecruitingTreatmentHead and Neck Carcinoma1
2Active Not RecruitingTreatmentSquamous Cell Carcinoma (SCC)1
2CompletedTreatmentDiffuse Intrinsic Brainstem Gliomas1
2CompletedTreatmentEsophageal1
2CompletedTreatmentGlioblastomas1
2CompletedTreatmentHead and Neck Carcinoma1
2CompletedTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentRecurrent Diffuse Pontine Gliomas1
2CompletedTreatmentStomach Neoplasms1
2Not Yet RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
2RecruitingTreatmentCancer, Breast1
2RecruitingTreatmentCervical Adenosquamous Cell Carcinoma / Cervical Squamous Cell Carcinoma In Situ / Neoplasms / Stage IB Cervical Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage III Cervical Cancer / Stage IVA Cervical Cancer1
2RecruitingTreatmentCervical Cancers1
2RecruitingTreatmentChildhood Brain Stem Neoplasm1
2RecruitingTreatmentDiffuse Intrinsic Pontine Glioma (DIPG)1
2RecruitingTreatmentHypopharyngeal Cancer / Oropharyngeal Cancers1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2RecruitingTreatmentLung Cancers1
2RecruitingTreatmentNasopharyngeal Carcinoma4
2RecruitingTreatmentNeoplasms, Esophageal1
2RecruitingTreatmentRecurrent Nasopharyngeal Carcinoma1
2RecruitingTreatmentStomach Neoplasms1
2TerminatedTreatmentAdvanced Non-Small Cell Lung Cancer1
2TerminatedTreatmentColorectal Cancers1
2TerminatedTreatmentMetastatic Non-Small Cell Lung Cancer1
2TerminatedTreatmentSquamous Cell Carcinoma of Anal Canal1
2Unknown StatusTreatmentAdvanced Colorectal Cancer1
2Unknown StatusTreatmentAdvanced Esophageal Carcinoma1
2Unknown StatusTreatmentConcurrent Chemoradiotherapy / Malignant Neoplasm of Stomach1
2Unknown StatusTreatmentEsophageal Cancers1
2Unknown StatusTreatmentEsophageal Squamous Cell Cancer1
2Unknown StatusTreatmentLocally Advanced Rectal Cancer1
2Unknown StatusTreatmentSCCHN1
2WithdrawnTreatmentAdenocarcinomas / Carcinoma NOS / Uterine Cervix Adenosquamous Carcinoma1
2WithdrawnTreatmentSquamous Cell Carcinoma of Esophagus1
2WithdrawnTreatmentStage IV Esophageal Squamous Cell Carcinoma2
2, 3CompletedNot AvailablePancreatic Cancer, Advanced or Metastatic1
2, 3CompletedTreatmentAdenocarcinomas / Esophageal Cancers1
2, 3SuspendedTreatmentSquamous Cell Carcinoma of Esophagus1
2, 3Unknown StatusTreatmentSquamous Cell Carcinoma of Esophagus1
3Active Not RecruitingTreatmentCervical Cancers1
3Active Not RecruitingTreatmentGastroesophageal Junction Cancer / Malignant Neoplasm of Stomach1
3Active Not RecruitingTreatmentMalignant Neoplasm of Nasopharynx1
3CompletedTreatmentAdults With Glioblastoma Multiforma1
3RecruitingTreatmentCarcinoma, Squamous Cell of Head and Neck1
3RecruitingTreatmentMalignant Neoplasm of Pancreas1
3RecruitingTreatmentProsthesis Survival1
3RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
3WithdrawnTreatmentCarcinoma NOS / Head and Neck Carcinoma1
4RecruitingTreatmentNasopharyngeal Carcinoma1
Not AvailableActive Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableCompletedNot AvailableDiffuse Instrinsic Ponitine Glioma1
Not AvailableUnknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on March 19, 2008 10:16 / Updated on June 04, 2019 06:21